A team of researchers directed by Frédéric Coin, Inserm Research Director at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg (a Joint Inserm/CNRS/University of Strasbourg Research Unit), has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy.
The mechanism of senescence - or premature cell ageing - can have an anticancer effect. This new work, conducted by Hugues de Thé and his team (Paris Diderot University/ Inserm/ CNRS/ AP-HP), was published in Nature Medicine on 12 January 2014.
In the fruit fly Drosophila and zebrafish, mechanical strain may activate the genetic cascade that initiates the formation of the future organs during embryogenesis. A discovery made by Emmanuel Farge (Inserm Research Director at Institut Curie) and his staff might explain the emergence of the first complex organisms more than 570 million years ago.
Research jointly conducted by investigators at Institut Gustave Roussy, Inserm, Institut Pasteur and INRA (French National Agronomic Research Institute) has led to a rather surprising discovery on the manner in which cancer chemotherapy treatments act more effectively with the help of the intestinal flora (also known as the intestinal microbiota).
An international study conducted on mice and coordinated by researchers from Inserm, CNRS and Université Paris-Sud[1] has paved the way towards personalized chronotherapy treatments. In an article published in the journal Cancer Research, the team has shown that the timing of optimal tolerance to irinotecan, a widely used anti-cancer drug, varies by 8 hours depending on the sex and genetic background of mice. They then developed a mathematical model...
In a lymphoma model, the scientists have been able to carry out real time in vivo imaging of the cellular events activated by the treatment and resulting in the destruction of tumor cells.
Some individuals are better able to fight cancer for many years compared with others. This ability to fight tumours depends on the immune response, as observed for colorectal cancers by Jérôme Galon, Research Director at Inserm, and his team, the Laboratory of Integrative Cancer Immunology, at the Cordelier Research Centre (Inserm/UPMC/Paris Descartes University). The investigators show that the proportions of immune system cells in and around the tumour change...
Une famille avec de nombreux cancers inexpliqués révèle que certaines prédispositions aux cancers du rein sont liées à des mutations du gène BAP1. Porté sur le chromosome 3, ce gène était déjà connu pour prédisposer à des cancers oculaires (mélanome uvéal) et de la plèvre (mésothéliome). Ces travaux réalisés par Marc-Henri Stern du laboratoire Génétique et Biologie des Cancers (Institut Curie/Inserm U830) en coordination avec le Pr Dominique Stoppa-Lyonnet...
Claire Hivroz, INSERM Research Director and her colleagues recently showed in an article published in Nature immunology how a specific protein known as VAMP7 is essential for transporting the signal produced by the ligand–TCR link.
The therapeutic efficacy of certain anti-cancer vaccines depends on how they are administered. This is what the team of researchers headed by Eric Tartour at the Paris-Centre de recherche Cardiovasculaire (Université Paris Descartes, INSERM Unit 970 PARCC, AP-HP), in collaboration with researchers from the CNRS , have just demonstrated.